# A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

> **NCT03526835** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merus B.V.** · enrollment: 523 (estimated)

## Conditions studied

- Advanced/Metastatic Solid Tumors
- Colorectal Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer
- NSCLC
- HNSCC
- Head and Neck Squamous Cell Carcinoma
- Esophageal Cancer

## Interventions

- **DRUG:** MCLA-158
- **COMBINATION_PRODUCT:** MCLA-158 + Pembrolizumab
- **COMBINATION_PRODUCT:** MCLA-158 + FOLFIRI
- **COMBINATION_PRODUCT:** MCLA-158 + FOLFOX

## Key facts

- **NCT ID:** NCT03526835
- **Lead sponsor:** Merus B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-05-02
- **Primary completion:** 2025-11
- **Final completion:** 2027-11
- **Target enrollment:** 523 (ESTIMATED)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03526835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03526835, "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03526835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*